PATENT DOCKET NO.: 20609/241 (PD 02036/02037)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED **CENTRAL FAX CENTER**

Applicants	:	Jennings et al.	Examiner: Maher M. Haddad	DEC 2 9 2005
Serial No.	:	10/619,323) Waner W. Haddad)	
Cnfrm. No.	:	8249) Art Unit:) 1644	
Filed	:	July 14, 2003		
For	:	METHODS OF MODIFYING BEHAVIOR OF CD9-EXPRESSING CELLS	· · ·	

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the September 29, 2005, written restriction requirement, applicants hereby elect Group 47 (i.e. claims 72-75) with traverse. Applicants traverse the restriction in its entirety, because the product and process claims can be searched without undue burden. For this reason, the written restriction requirement is improper and, therefore, applicants respectfully request that the written restriction requirement be withdrawn in its entirety.

In response to the election of species requirement, applicants hereby elect with traverse the polypeptide fragments of CD9 comprising SEQ ID NO: 3, which is generic to SEQ ID NOS: 4-6. Claims readable upon the elected species (subgenus, actually) include claims 72-75. Applicants traverse the election of species requirement, because both the subgenus and the three species can be searched and examined without undue burden.

Respectfully submitted,

Date: December 29 2005

NIXON PEABODY LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051

Telephone: (585) 263-1128 Facsimile: (585) 263-1600

Edwin V. Merkel

Registration No. 40,087

CERTIFICATE OF TRANSMISSION 137 CFR 1.8(a)]

I hereby certify that this correspondence is being facsimile transmitted to the USPTO at (571) 273-8300, on December 29, 2005.

December 29, 2005

Edwin V. Merkel

R894347.1